Figure 2.

Outline of a proposed model for risk assessment, monitoring and management of patients undergoing chemotherapy. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; cTn, cardiac troponin; ECG, electrocardiogram; HTN, hypertension; PAD, peripheral arterial disease; TTE, transthoracic echocardiogram. Reprinted from Mayo Clinic Proceedings, Volume 89(9), Joerg Herrmann, MD, Amir Lerman, MD, Nicole P. Sandhu, MD, PhD, Hector R. Villarraga, MD, Sharon L. Mulvagh, MD, and Manish Kohli MD, 2014, pages 1287–1306, with permission from Elsevier.